Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cp-cov03

Preclinical

HHyundai Bioscience Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

DengueRecruiting

DenguePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Dengue

NCT07576868

Clinical

Trials by Indication[1]

Dengue1 trial

A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) / Dengue and Dengue-like Illness Patients (Part 2)

Recruiting·HHyundai Bioscience Co., Ltd.·Preclinical·NCT07576868·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cp-cov03. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cp-cov03. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hyundai Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: HHyundai Bioscience Co., Ltd.

Related News